#AIDS2016 ASSESSMENT OF THE WORLD HEALTH ORGANIZATION EARLY WARNING INDICATORS OF HIV DRUG RESISTANCE IN NAMIBIA FOR PUBLIC HEALTH ACTION,

Slides:



Advertisements
Similar presentations
World Health Organization Surveys of Transmitted and Acquired HIV Drug Resistance in Resource Limited Settings CROI 2011 S Bertagnolio*, K Kelley*, A Saadani.
Advertisements

February 2006 WHO's Contribution to Scaling Up towards Universal Access to HIV/AIDS Prevention, Care and Treatment Department of HIV/AIDS.
Results Introduction Background and Objectives  Identifying effective and cost-effective ways to improve adherence to antiretroviral therapy (ART) is.
High rates of survival, virologic suppression and immune reconstitution among patients receiving second-line ART in the Indian national programme B.B.
Preventing HIV Drug Resistance with Programmatic Action Michael R. Jordan MD MPH.
1 Measuring adherence using electronic dispensing data: nationwide electronic monitoring in Namibia Dr. David Mabirizi – Country Director MSH Namibia Third.
The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Linda-Gail Bekker The implementation of this project was made possible.
Integrating Evidence-Based Practice Into QI to Improve Patient Outcomes in HIV: Viral Load Suppression Victoria Lieb, ACRN, MPH; Carla Rossi, MD; Jaime.
Effects of patient tracing on estimates of lost to follow-up, mortality and retention in antiretroviral therapy programs in low-middle income countries:
Dr. Yogan Pillay Deputy Director General National Department of Health, South Africa Monday 1 July 2013 OPERATIONAL AND PROGRAMMATIC CONSIDERATIONS IN.
Kevin Fenton, MD, PhD, FFPH Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Centers for Disease Control and Prevention.
Using Mobile Technology to Strengthen HIV/AIDS Management in Remote Areas Authors: (1)Kunda, Mwape; (2)Pereko, Dawn; (2)Sumbi, Victor; (2)Mwinga, Samson;
The Namibia Treatment Literacy Approach: Empowering Patients with Knowledge on Antiretroviral Therapy Through Audiovisual Materials Authors Francis Kalemeera.
Presentation Title Presenter(s) Centers for Disease Control and Prevention AIDS Turning the Tide Together.
Effects of Patient Tracking Systems and Providers Incentives on Patient Appointment Keeping Rwanda Pilot Study Report Nyamusore Jose 1 *, Hinda Ruton 1,
Tracking of Inter-Facility Patient Transfers and Retention on Antiretroviral Treatment in Namibia Presenter Naita Nashilongo Ministry of Health and Social.
Models of Care for Paediatric HIV Miriam Chipimo MD MPH Reproductive Health & HIV&AIDS Manager, UNICEF, Malawi.
Elliot Raizes, MD HIV Care and Treatment Branch AIDS 2012: WHO Satellite Symposium HIV Drug Resistance Surveillance and Control: A Global Concern July.
Downloaded from Current Status of ART Opportunities & Challenges Kibrebeal Melaku,MD Associate Professor.
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
HIV/AIDS Track Session. Key Points Application of international reference price list during a national tender is a valuable tool for achieving optimal.
High-impact interventions. Number of people living with HIV who were not receiving antiretroviral therapy, 2014 and 2015 Source: UNAIDS estimates, 2014.
Dr Rochelle Adams ACC Project Manager On behalf of the ACC team AWACC November 2015 Health systems Strengthening for Success and Sustainability.
Dr. Prosper Chonzi MBChB, MPH, MBA Director of Health Harare City 30 November 2015 Harare – A Fast Track City.
United Republic of Tanzania Ministry of Health & Social Welfare MINISTRY OF HEALTH AND SOCIAL WELFARE NATIONAL AIDS CONTROL PROGRAM HIV CARE AND TREATMENT.
1 Uses of Data from the WHO HIV Drug Resistance Strategy: 1. Monitoring of HIVDR emerging in treated groups in sentinel ART clinics HIV Drug Resistance.
Commentary Thailand national guidelines for implementing HIV prevention among men who have sex with men and transgender populations As of March 2013 Frits.
Building Pharmaceutical Sector Capacity in Namibia: An Innovative Initiative to Recruit and Retain Pharmacy Staff for Public Service Nwokike, J. 1, D.
Prevention of Mother-to-Child Transmission of HIV: Scale-up of Critical Services in Uganda (District- based Approach) Edward Bitarakwate, MD, MPH Technical.
From Aggregate Indicators to Impacting Patients - Data Use to Inform Treatment and Improve Care Ian Wanyeki Track 1.0 Implementers Meeting Dar Es Salaam.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
New WHO Guidelines on Person centred monitoring
PRESENTED AT THE 9TH IAS CONFERENCE ON HIV SCIENCE - PARIS, FRANCE
Differentiated Monitoring & Evaluation
How differentiated care supports “Tx all” and Dr
Demanding a high impact HIV response: civil society advocacy and the President’s Emergency Plan for Aids Relief (PEPFAR) Dorothy Namutamba International.
Presented to the AIDS 2016 Conference
BIRUTE SEMENAITE, MEDICAL DIVISION OF THE PRISON DEPARTMENT
ART Adherence Clubs South Africa
ESCP 2017 Workshop, Leiden, the Netherlands, June
World Health Organization
Utilizing research as an opportunity to strengthen
A COLLABORATIVE APPROACH TO ESTABLISH PREDICTORS
ART Adherence Clubs South Africa
Building Health Systems to Deliver People-centered Health Services
HIV Quality Improvement (QI) and the Treatment Cascade: How QI has Impacted Reach, Recruitment, Testing, Treatment, and Retention Efforts in Thailand?
Is Your Patient Engaged in Care
Antiretroviral therapy coverage in sub-Saharan Africa,
Outline Session 7:00 FRSA0701 Welcome and introductions : WHO general approach to cascade analysis framework : From Cascade Analysis to Action  Jesus M.
Dr. Velephi Okello, Principal Investigator, MaxART Trial
Jepkoech Kottutt1, Emilia D. Rivadeneira2, Susan Hrapcak2
Global Action Plan on HIVDR 2018 Progress Report
WHO 2015 GUIDELINES AND FAST TRACKING TOWARDS : Regional perspective
USAID STRENGTHENING THE CARE CONTINUUM PROJECT (The Care Continuum)
Summary Sheet Figures and Maps
Summary Sheet Figures and Maps
Summary Sheet Figures and Maps
Ministry of Health, Kenya
Summary Sheet Figures and Maps
Summary Sheet Figures and Maps
Natella Rakhmanina, MD, PhD AIDS 2018, Amsterdam, the Netherlands
Silvia Bertagnolio, MD HIV Department World Health Organization
Illustrative Cluster Detection and Response Strategy
Stakeholder engagement and research utilization: Insights from Namibia
HIV Recency Testing in Rwanda
Start Free, Stay Free, AIDS Free
Update on global progress in ART
Why Quality Matters in ART Programs
Dr. Grace Namayanja – Kaye 24 July 2019
For a healthy Zambia.
Presentation transcript:

#AIDS2016 ASSESSMENT OF THE WORLD HEALTH ORGANIZATION EARLY WARNING INDICATORS OF HIV DRUG RESISTANCE IN NAMIBIA FOR PUBLIC HEALTH ACTION, 2015 Nicholus Mutenda 1, Tuli Nakanyala 1, Ndapewa Hamunime 1, Tadesse Mekonen 1, Francina Tjituka 1, Salomo Natanael 1, Greatjoy Mazibuko 2, Samson Mwinga 2, David Mabirizi 3, Evans Sagwa 2, Helena Walkowiak 4, Alexandra Kiesling 5, Samuel Aptekar 5, Michael R. Jordan 5,6, Steven Y. Hong 5,6 1 Directorate of Special Programmes, Republic of Namibia Ministry of Health and Social Services, Windhoek, Namibia, 2 Systems for Improved Access to Pharmaceuticals and Services program, Management Sciences for Health, Windhoek, Namibia, 3 Systems for Improved Access to Pharmaceuticals and Services program, Management Sciences for Health, Arlington, USA, 4 Systems for Improved Access to Pharmaceuticals and Services program, Management Sciences for Health, New York USA, 5 Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, USA, 6 Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, USA Abstract no. TUPDB0101

#AIDS2016 Background Early warning indicators (EWIs) of HIV drug resistance (HIVDR) – foundational element of the World Health Organization (WHO) public health strategy to minimize and monitor emergence of HIVDR in countries rapidly scaling up antiretroviral treatment (ART) – site-specific, quality-of-care indicators that assess factors associated with virological failure and emergence of HIVDR – identify gaps in service delivery for which corrective action can be taken at the ART site or program level – provide necessary program context for interpretation of WHO surveys of HIVDR – should be monitored annually at all treatment sites and integrated into ART program M&E and continuous quality improvement initiatives Namibia has instituted a routine EWI monitoring system and developed HIVDR survey strategies

#AIDS2016 Methods In 2015, Namibia abstracted the following WHO EWIs: – On-time Pill Pick-up – Retention in Care at 12 months – Pharmacy Stock-outs – Dispensing Practices – Viral Load Suppression at 12 months – Viral Load Completion at 12 months EWIs abstracted from adult and paediatric patients from all ART sites in the state health sector: 50 main ART sites and 163 outreach points WHO-recommended definitions and targets used, based on three classifications: – green (excellent performance, achieving desired level) – amber (fair performance, not yet at desired level) – red (poor performance, below desired level) – grey (insufficient data)

#AIDS2016 Geospatial location of 213 ART sites for EWI monitoring, 2015

#AIDS2016 Results On-time Pill Pick-up: – Adults: 45% of sites (excellent >90% or fair 80-90%) – Children: 40% of sites Retention in Care at 12 months – Adults: 54% of sites (excellent >85% or fair 75-85%) – Children: 38% of sites Pharmacy Stock-outs – Adults: 5% of sites (excellent 100% of months with no stock-outs) – Children: 14% of sites Dispensing Practices – Adults: 97% of sites (excellent 0% mono- or dual-therapy) – Children: 91% of sites Viral Load Suppression at 12 months – Low rates of Viral Load Completion among patients eligible for routine viral load testing significantly affected monitoring of Viral Load Suppression

#AIDS2016 Conclusion Namibia has successfully institutionalized EWI monitoring into routine ART program functioning Strengthening patient adherence, retention in care, and ensuring the continuous availability of ART medicines are all high priorities to minimize emergence of HIVDR and achieve the (HIV epidemic control) goals Improving routine viral load monitoring and data capturing is a priority to enable monitoring of viral load suppression rates As a result of these data, program leaders and healthcare providers in regions throughout the country are implementing service quality improvement projects and operational research to improve patient care and minimize the emergence of HIVDR